Dr. Raymond H. Mak, MD

Dr. Mak practices at Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Mak's NPI, 1285784041, was assigned on January 11, 2007. Dr. Mak graduated from Harvard Medical School in 2006. Dr. Mak holds Massachusetts license 235436.

Dr. Mak's primary practice is Brigham and Women's Hospital, at 75 Francis Street, Boston, MA 02115 in Suffolk County. The practice phone is (617) 732-5500.

Dr. Mak's primary practice is Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Mak is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Massachusetts General Physicians Organization (MGPO). Dmand AI also links Dr. Mak to 3 more medical groups and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mak practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Mak's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Mak is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Mak's licenses on file in 7 states: Massachusetts, Maine, Connecticut, Florida, Rhode Island, New Hampshire and New York.

Dmand AI lists bone cancer radiation and lung cancer radiation among the conditions Dr. Mak treats.

CMS data shows 1,505 Medicare services from Dr. Mak across 14 procedure codes in 2024, for 229 Medicare patients. Medicare paid $137,232 for them.

CMS counts 229 Medicare patients who saw Dr. Mak in 2024. The largest group is 75 to 84, with 99 patients. 75% of them have cancer, and 75% have high blood pressure. 14% are also on Medicaid. Their average risk score is 2.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mak's median patient age at 75, with 46% women.

In 2021, Dr. Mak wrote 11 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $73 in total drug cost. In 2019, CMS named 12 claims across 1 drug.

Dr. Mak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mak as offering telehealth.

Dmand AI links 182 papers to Dr. Mak, published from 2009 to 2025. 2024 was the busiest year, with 23. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Radiosurgery. Dr. Mak has published most often in Int J Radiat Oncol Biol Phys. Dr. Mak's most frequent co-authors are Elizabeth H. Baldini, MD, MPH, Katelyn Mae Atkins, MD and Aileen B. Chen, MD.

Dmand AI links Dr. Mak to 4 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Laryngeal Neoplasms and Liver Neoplasms. Brigham and Women's Hospital sponsors the most, 2.

CMS Open Payments shows 37 general payments to Dr. Mak from 5 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 65% of the total. AstraZeneca Pharmaceuticals LP paid the most, $23,849.

Dmand AI lists 1 award for Dr. Mak, most recently CMS Stage 1 2012 in 2012.

Dr. Mak graduated from Harvard Medical School in 2006. Dr. Mak is a member of ASTRO, ASCO and RSNA.

Dr. Mak is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.